Adamas Pharmaceuticals (ADMS) Stock Rating Upgraded by Zacks Investment Research

Adamas Pharmaceuticals (NASDAQ:ADMS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Tuesday.

According to Zacks, “Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. “

Get Adamas Pharmaceuticals alerts:

Several other analysts have also weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Adamas Pharmaceuticals in a research note on Monday, November 5th. Piper Jaffray Companies set a $23.00 price objective on shares of Adamas Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday. Northland Securities reiterated a “buy” rating and issued a $28.00 price objective on shares of Adamas Pharmaceuticals in a research note on Tuesday. BidaskClub upgraded shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, February 25th. Finally, Mizuho reiterated a “hold” rating and issued a $11.00 price objective on shares of Adamas Pharmaceuticals in a research note on Friday, January 11th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $23.88.

Adamas Pharmaceuticals stock traded down $3.99 during mid-day trading on Tuesday, hitting $8.16. 5,170,283 shares of the stock were exchanged, compared to its average volume of 462,741. The company has a debt-to-equity ratio of 1.01, a quick ratio of 8.74 and a current ratio of 8.95. Adamas Pharmaceuticals has a 12 month low of $7.42 and a 12 month high of $32.90. The firm has a market cap of $303.70 million, a price-to-earnings ratio of -2.06 and a beta of 1.41.

Adamas Pharmaceuticals (NASDAQ:ADMS) last released its quarterly earnings results on Monday, March 4th. The specialty pharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.36) by $0.30. Adamas Pharmaceuticals had a negative net margin of 617.27% and a negative return on equity of 106.74%. As a group, equities research analysts predict that Adamas Pharmaceuticals will post -5.21 EPS for the current fiscal year.

Large investors have recently added to or reduced their stakes in the company. Pacer Advisors Inc. acquired a new stake in shares of Adamas Pharmaceuticals during the 3rd quarter valued at $104,000. First Mercantile Trust Co. increased its stake in Adamas Pharmaceuticals by 43.2% in the fourth quarter. First Mercantile Trust Co. now owns 5,765 shares of the specialty pharmaceutical company’s stock valued at $49,000 after purchasing an additional 1,740 shares in the last quarter. Advisor Group Inc. increased its stake in Adamas Pharmaceuticals by 252.0% in the fourth quarter. Advisor Group Inc. now owns 6,300 shares of the specialty pharmaceutical company’s stock valued at $54,000 after purchasing an additional 4,510 shares in the last quarter. Tower Research Capital LLC TRC bought a new stake in Adamas Pharmaceuticals in the third quarter valued at approximately $162,000. Finally, Jane Street Group LLC bought a new stake in Adamas Pharmaceuticals in the third quarter valued at approximately $324,000. Institutional investors own 79.76% of the company’s stock.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.

See Also: What is the price-sales ratio?

Get a free copy of the Zacks research report on Adamas Pharmaceuticals (ADMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com